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Abstract The concept of a precise region in which to find
the lymph nodes that drain the lymph directly from the
primary tumor site can be traced back to a century ago to the
observations of Jamieson and Dobson who described how
cancer cells spread from cancer of the stomach in a single
lymph node, which they called the ‘‘primary gland’’.
However, Cabanas was the first in 1977 to realize the im-
portance of this concept in clinical studies following lym-
phography performed in patients with penile cancer. Thanks
to Morton’s studies on melanoma in 1992, we began to
understand the potential impact of the sentinel lymph node
(SN) on the surgical treatment of this type of cancer. The
use of a vital dye (blue dye) administered subdermally in the
region surrounding the melanoma lesion led to the identi-
fication of the sentinel node, and the vital dye technique was
subsequently applied to other types of solid tumors, e.g.
breast, vulva. However, difficulties in using this technique
in anatomical regions with deep lymphatic vessels, e.g.
axilla, led to the development of lymphoscintigraphy,
started by Alex and Krag in 1993 on melanoma and breast
cancer and optimized by our group at European Institute of
Oncology (IEO) in Milan in 1996. Today, lymphoscintig-
raphy is still considered as the most reliable method for the
detection of the SN. In 1996, a new method for the local-
ization of non-palpable breast lesion called radioguided
occult lesion localization (ROLL) was also developed at
IEO. Retrospective and prospective studies have since
shown that the ROLL procedure permits the easy and ac-
curate surgical removal of non-palpable breast lesions,
overcoming the limitations of previous techniques such as
the wire-guided localization. The purpose of this paper is to
describe the evolution of SN biopsy and radioguided sur-
gery in the management of breast cancer. We also include a
review of the literature on the clinical scenarios in which SN
biopsy in breast cancer is currently used, with particular
reference to controversies and future prospects.
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Introduction
The sentinel lymph node (SN) technique and radioguided
occult lesion localization (ROLL) of non-palpable tumors
have changed the way we evaluate and treat early breast
cancer, reducing the morbidity and improving the quality of
life of patients. The concept of ‘‘sentinel lymph node’’ is
intimately linked to the notion that, in the majority of pa-
tients, the metastatic spread of cancer through the lymphatic
system follows a unidirectional, orderly and predictable
pattern [1, 2]. On the basis of this assumption, the histo-
logical evaluation of the ‘‘sentinel node’’, i.e. the first lymph
node that drains the lymph directly from the primary tumor,
enables us to exclude the presence of malignant cells in
other lymph nodes. Therefore, the status of the SN is ca-
pable of accurately predicting the pathological state of the
subsequent regional lymph node stations. Cabanas was the
first to understand the importance of this concept in 1977 in
clinical studies performed on patients with penile cancer
[3]. He not only managed to locate the SN (which he mis-
takenly believed to be located in a fixed anatomic site), but
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also observed a correlation between disease status and
lymph node involvement, concluding that if the SN biopsy
was negative, there would be no need to perform further
surgical treatments.
During the 1990s, the potential impact of SN on the
surgical treatment of cancer was further demonstrated in
the clinical setting [4, 5] by the use of a vital dye (blue dye)
administered subdermally in the region surrounding the
lesion. However, the low success rate of this method led to
the development of lymphoscintigraphy, subsequently ac-
knowledged as the most reliable method for SN detection.
Alex and Krag [6] were the first to publish results on
lymphoscintigraphy in melanoma and breast cancer in
1993, after which the technique was optimized by our
group at the European Institute of Oncology (IEO) in Milan
in 1996–1998 [7, 8]. Since then, the procedure has been
used in thousands of breast cancer patients throughout
Europe. The first randomized trial comparing total axillary
dissection with SN biopsy was performed by Veronesi and
co-workers [9] on patients with breast cancers \2 cm in
size. After preliminary results favoring SN biopsy were
made known, new patients refused to be randomized and
the study was forced to close with a recruitment of 516
patients (257 in the SN biopsy ? total axillary dissection
arm vs. 259 in the SN biopsy only arm). Of the 257 patients
in the axillary dissection group, 32.3 % of patients had a
positive SN and 174 had a negative sentinel node (67.7 %).
Of the 259 patients in the SN group, 92 had a positive SN
(35.5 %), and 167 had a negative SN (64.5 %). The IEO
results were further confirmed by those of the NSABP B-32
study [10, 11], i.e. sentinel lymph node biopsy accurately
predicted axillary status in 96.9 % of patients, with a false-
negative rate of 8.8 %. Moreover, post-operative mor-
bidities were much less frequent in the sentinel node group.
In 1996, in addition to the SN study for the optimization of
the lymphoscintigraphy technique, a new method for the
localization of non-palpable breast lesions called ROLL
(radioguided occult lesion localization) was also developed
by our group [12, 13].
Wire-guided localization (WGL) has been the standard
technique for many years to localize non-palpable lesions
[14]: the surgeon uses a thin, hooked wire inserted under
ultrasound or stereotactic guidance into the lesion to iden-
tify and remove it. However, numerous studies [15, 16]
have reported a high rate of positive margins after wire
localization (between 14 and 47 %) resulting in the need for
re-operation or in a greater incidence of local recurrence.
In the ROLL technique, a radioactive tracer
(99mTcMAA) is injected into the tumor under stereotactic
or ultrasound guidance the day before surgery. A handheld
gamma probe similar to that of SN biopsy is used to guide
intra-operative lesion identification and surgical resection
[12]. Several publications have suggested that this
technique has led to decreased positive margin rates, a
lower incidence of re-operation and more accurate surgical
excision [17–21].
In the present article, we report some of the most im-
portant developments made in the fields of SN biopsy and
ROLL technique in breast cancer.
SN methodological aspects
Despite its widespread use, there is still no general con-
sensus on the correct methodology of the SN biopsy pro-
cedure and numerous open questions remain to be resolved,
e.g. kind of tracer to use, route of injection, or correct
imaging technique (static, SPECT or SPECT/CT).
Radiotracers
The radiopharmaceutical used for SN biopsy must meet the
following requirements:
1. It must permit the visualization of the lymphatic
channels leading from the site of administration to the
corresponding lymph node.
2. It must be retained in the first lymph node(s) encoun-
tered along such lymphatic pathways. Intranodal
retention is due to the macrophages lining the sinusoid
spaces of lymph nodes whose main function is to clear
the affluent lymph of particulate matters through an
active, saturable phagocytosis process [7, 22].
The efficient uptake of radiolabelled particles in lymph
nodes is dependent on the size of the particles, the surface
charge and on a preliminary reaction of opsonization that
activates membrane receptors on the macrophages and
consequently phagocytosis of the radiocompound [7, 22–
27]. These characteristics are shared by different formu-
lations, both inorganic (198Au-colloid, 99mTc-antimony
sulfide, 99mTc-sulfur colloid, 99mTc-stannous fluoride,
99mTc-rhenium sulfide) and organic (micro-or nanocolloid
human albumin). After interstitial administration, the col-
loidal particles pass into the lymphatic circulation with a
speed that is inversely proportional to particle size [25, 28].
In our experience, the ideal tracer is composed of par-
ticles between 100 and 200 nm in size to obtain the best
compromise between speed of drainage and accumulation
in the sentinel node. In fact, colloidal tracer particles
smaller than 50 nm drain rapidly into the lymphatic vessels
but also pass easily into second- and third-level lymph
nodes. On the other hand, tracers composed of particles
[300 nm do not drain easily into the lymphatic system,
making it difficult to visualize the SN. In our first series of
240 consecutive patients, the mean number of lymph nodes
visualized using radiocolloid particles ranging in size
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between 15 and 50 nm was 2.1 (SD 1.1), 1.6 (SD 0.8) for
tracer particles B80 nm and 1.3 (SD 0.5) for larger parti-
cles [7]. Colloidal tracer particles of 100–200 nm are not
commercially available and currently the most widely used
radiopharmaceutical in the USA is the technetium-labeled
sulfur colloid in a non-filtered (with particles ranging from
about 15 to 5000 nm) or filtered form.
In Europe, the majority of Nuclear Medicine Centers use
human serum albumin particles of 40–100 nm
(95 % \ 80 nm), whereas antimony trisulfide (range
3–30 nm) is commonly used in Australia and Canada.
With regard to the timing of preoperative scintigraphy, it
should be taken into account that the amount of marked
colloidal particles detectable in the SN 15–18 h after in-
jection is low; in fact, only 1 % of the subdermally injected
activity remains in the lymph node and this percentage is
further reduced if the dose is administered via peritumoral
injection [7]. In general, lymphoscintigraphy performed in
the afternoon prior to surgery (15–18 h before surgery)
leads to optimal lymphatic drainage for radiocolloids of
any particle size. Conversely, if only smaller radiocolloids
are available, it is better to perform the imaging study and
surgical procedure on the same day to avoid the colloids
draining to second- or third-echelon nodes before surgery.
A colloid labeled with 99mTc is used for the ROLL
technique: a review of the literature [29] reveals that
macro-aggregates are the tracer of choice in about 67 % of
cases and 99mTc-nanocolloids in the remaining 33 %,
without, however, any difference in the detection rate of
lesions during surgery.
Methods of inoculation
The optimal injection approach has been much debated
over the past 18 years. The different methods proposed can
be divided into two main categories: deep injection (in-
tratumoral, peritumoral or subtumoral) and superficial
(intradermal, subdermal, subareolar or periareolar). Multi-
ple studies have been carried out to compare outcomes
using the different injection methods, the majority showing
equivalent rates for the detection of SN, whereas a few
reported that periareolar and subareolar injections are
slightly better than peritumoral injection. Only one study
[30] observed a significant difference between superficial
and deep injection. Two prospective randomized trials on
inoculation methods have been published to date [31, 32]
without, however, reaching definitive conclusions. Povoski
et al. reported that the rate of identification of the SN was
higher with intradermal injection, while Rodier concluded
that periareolar injection was the most effective route of
administration because of the 99.11 % SN detection rate
and the high concordance (95.56 %) between blue dye and
radiotracer. Data from a study conducted by our group [7]
comparing intradermal and peritumoral injection revealed
no significant differences in the SN detection rate, the only
variation worthy of note being the longer time required for
SN visualization by peritumoral administration.
Other factors should be considered when deciding on the
injection method. One major advantage of superficial in-
jection is that it is easy to perform and results in less in-
terference with scintigraphic imaging. Moreover, this
method does not require ultrasound guidance, even in cases
of non-palpable breast cancer. Deep injections are difficult
to perform in such patients and often ultrasound or
stereotaxic guidance, which also facilitate the detection of
extra-axillary nodes.
We believe that both deep and superficial injection ap-
proaches are valid techniques and often complementary;
combinations of injection techniques (either peritumoral
and subareolar/periareolar injections [33] or subdermal/
peritumoral injection [34]) may improve detection accu-
racy and decrease false-negative rates (FNR). This is sup-
ported by the results from Suami et al.’s [35] human
cadaver study of breast lymphatic anatomy which showed
that although the majority of superficial lymph vessels of
the breast drain to only one sentinel node some show al-
ternative lymphatic drainage. Our current approach is to
use subdermal injection if the tumor is localized superfi-
cially and peritumoral administration when the lesion is
located deeper within the mammary gland.
Imaging
The acquisition of images after administration of the ra-
diopharmaceutical is considered an indispensable part of
the process of identification of the SN. Such images, in
fact, provide basic information on pathways that are
unobtainable when only the probe is used. The images
acquired after the injection of the colloid greatly enhance
the accuracy of the surgical resection [36]; this is especially
true when the SN is localized near the site of injection of
the tracer, or when extra-axillary lymph nodes are in-
volved, e.g. internal mammary chain (IMC) nodes. The
time required to perform the preoperative scintigraphy
varies on the basis of the tracer used, ranging between 15
and 90 min after injection [37–39], while surgery can be
delayed for up to 16–18 h after injection with radiocolloids
of 200–1000 nm [40].
It has been seen that both SPECT and SPECT/CT are
useful in specific conditions [41–44]; EANM guidelines
[45] recommend the use of tomographic imaging in cases
of non-visualization of SN in planar images, especially in
obese patients, in the presence of extra-axillary drainage or
in sites that are difficult to visualize, e.g. multiple drainage
sites, IMC nodes, intramammary lymph nodes, contralat-
eral axilla nodes or surgically resected sites. The use of
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SPECT/CT is also advisable when conventional images are
difficult to interpret, for example in the event of con-
tamination or when SN is located near the site of injection.
Indications and controversies
The localization and biopsy of the SN represent the
‘‘standard of care’’ for the staging of axillary lymph nodes
in breast cancer patients. These procedures have also re-
placed axillary lymph node dissection (ALND), performed
routinely in the past, in women with stage I–II breast
cancer with no evidence of axillary lymph node involve-
ment [7, 45, 46].
Patients with negative SN biopsy do not require ALND,
as concluded by American Society of Clinical Oncology
guidelines [47] on the basis of results from large random-
ized trials conducted in both Europe and the US [48–52]
(Table 1). However, ALND remains the standard treatment
for patients with axillary metastases identified by SN
biopsy and is also performed in cases in which the SN is
not identified during surgery.
Minimal lymph node involvement
One area that requires further investigation is that of the
detection of micrometastases and/or isolated tumor cells
(ITCs) in SN. Micrometastases are defined as a tumor de-
posit between 0.2 and 2.0 mm and with more than 200
cells, while ITCs are clusters of cells no[0.2 mm in size or
with fewer than 200 cells [53].
Between 2001 and 2010, the International Breast
Cancer Study Group (IBCSG) 23-01 trial recruited women
with primary breast cancer B5 cm and only SN mi-
crometastatic disease from 27 institutions. The women
were randomized to SN only or standard complete ALND.
At a median follow-up of 5 years, the axillary recurrence
rate was \1 % in both arms and survival outcomes were
similar in the ALND and SLNB-alone-groups (DFS: 84 %
vs 88 %, respectively) [52]. Comparable results were
obtained in the multi-institutional ACOSOG study [51]
which evaluated the safety of not performing ALND in a
subgroup of patients with SN-detected micrometastatic
disease. Patients were randomized to either complete
ALND or observation.
Results showed that there was no difference in local re-
currence or disease-free survival between patients under-
going observation and ALND at a median follow-up of
6.3 years. Five-year overall survival in the axillary dissec-
tion arm was 91.8 % [95 % confidence interval (CI):
89.1–94.5 %] vs. 92.5 % in the observation arm (95 % CI:
90.0–95.1 %). Five-year disease-free survival was 82.2 %
in the axillary dissection arm (95 % CI: 78.3–86.3 %) vs.
83.9 % in the observation group (95 % CI: 80.2–87.9 %).
The 2011 St. Gallen Consensus Conference [54] concluded
that micrometastases in the SN are not an indication for
ALND, irrespective of the type of breast surgery performed.
Ductal carcinoma in situ (DCIS)
DCIS metastasizes to axillary lymph nodes in a very small
proportion of patients (1–2 % of cases) and for this reason
the National Cancer Institute does not recommend SN
biopsy [55]. However, the diagnosis of DCIS is often
subject to sampling error, and a certain percentage of pa-
tients with an initial diagnosis of DCIS are actually found
to have invasive carcinoma with axillary metastases after
surgery. The role of SN biopsy in the management of DCIS
is much debated: some authors recommend its use because
of the somewhat alarming rate of diagnostic errors [56, 57],
while others advise against it on the basis of the low in-
cidence of lymph node involvement in patients with true
DCIS [58]. A meta-analysis of 22 published studies re-
vealed that the incidence of SN metastases in patients with
a preoperative diagnosis of DCIS was 7.4 % (95 % CI
6.2–8.9), significantly higher than that in patients with a
definite post-operative diagnosis of DCIS (3.7 %) [59]. SN
biopsy is currently recommended in patients with DCIS
submitted to mastectomy; in patients in whom breast
conservation is planned, SN biopsy can be performed later
if invasion is detected in a surgical specimen. Nevertheless,
some centers opt to perform SN biopsy in DCIS patients
because they sustain that wide local excision may alter
lymphatic drainage, especially to IMCs, making a subse-
quent SN biopsy difficult [60].
SN biopsy after prior breast or axillary surgery
The SN method is normally restricted to women who have
not already undergone surgery as it is important to have an
intact lymphatic system for optimal drainage. However,
there is evidence to suggest that SN biopsy can also be
performed after either conservative or radical surgical
treatment: Port et al. [61], in their study of 117 patients
previously submitted to surgery, reported an SN detection
rate of 55 % which was directly proportional to the number
of lymph nodes removed during the first intervention, and
was more successful after a previous SLN biopsy than a
previous ALND (74 vs. 38 %). In this series, although
there were no cases of locoregional recurrence at a mean
follow-up of 2.2 years, 5 % of patients developed distant
recurrence. Cox et al. [62] reported an SN detection rate of
80 % in a series of 56 patients, with no axillary recurrence
after 2 years. The same group subsequently published data
on patients who had previously undergone ipsilateral
lymph node dissection, this time reporting a detection rate
of only 29 % [63].
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The experiences reported in the literature suggest that
distant metastases are more frequently detected than axil-
lary lymph node recurrence when SN biopsy is performed
as second surgery, thus lessening its impact from a prog-
nostic or therapeutic point of view.
Pregnancy
There are obvious difficulties in the management of breast
cancer during pregnancy, e.g. how to evaluate nodal status.
Although this was not a problem when axillary dissection
was the standard staging procedure, careful assessment of
the risks and benefits of the SN technique is required in this
population. The technique in both melanoma and breast
cancer uses a standard dose of 11–111 mBq of 99mTc-
nanocolloids. In pregnant patients, the dose absorbed by
the fetus is about 0.43 cGy [64] and the risk of embryonic
or fetal genetic defects ranges from 0.024 to 0.099 % per
cGy [65], whereas the lowest threshold for fetal terato-
genicity has been estimated at 5 cGy [66]. Although
studies conducted on pregnant women [64] suggest that the
radionuclide does not put the fetus at risk and that the
technique can be used safely in this population, there are
still too few data to confirm this. For this reason, written
informed consent must be obtained from the patient before
the procedure can be undertaken.
Sentinel lymph node of IMNs
The SN technique allows for a better assessment of lymph
node status in IMNs which are generally evaluated in the
standard surgical procedure. The presence of IMN metas-
tases is a poor prognostic factor [67] and is correlated with
a higher incidence of distant metastases and reduced sur-
vival [68, 69]. The involvement of IMNs is more frequent
in tumors located in inner breast quadrants, even in cases of
subcentimeter lesions. The risk of distant metastases
increases by 30 % in inner quadrant lesions, with a 20 %
higher mortality; in particular, the risk of metastasis to
IMN is associated with age (decreases with increasing age),
primary tumor size and the presence of axillary metastases
[70].
From a methodological point of view, intraparenchymal
or peritumoral administration of a 0.2–0.3 ml volume of
15–18 MBq of 99mTc albumin colloids is required to vi-
sualize IMNs. This method of administration permits at
least one IMN to be visualized in 60 % of tumors, whereas
intra/subcutaneous administration is only effective in
1–2 % of cases. Furthermore, the probability of visualizing
IMNs increases if the injection is made in the inner
quadrants of the breast. However, it must be underlined
that tumors located deep within the breast, especially in
inner quadrants, probably drain to IMNs, making it nec-
essary to perform lymphoscintigraphy to localize the SN
[71].
The role of IMN biopsy remains to be defined. There is
some evidence that the mapping of IMNs improves staging
and facilitates therapeutic decision making (radiotherapy or
systemic therapy), but this has yet to be confirmed [72].
ROLL and SNOLL
SN biopsy and ROLL can be used in combination
(SNOLL) for cancers or high-grade infiltrating ductal aty-
pia. A recent review [73] analyzed the results from seven
studies evaluating 983 patients with non-palpable breast
cancer. The rate of complete resection with negative mar-
gins ranged from 82 to 90.5 %, while 2–12 % of patients
required re-operation.
The authors concluded that, although SNOLL is a fea-
sible, safe and effective procedure for the treatment of non-
palpable breast cancers, multicenter randomized trials are
needed to validate the methodology before it can be ap-
proved as a standard of care in this type of tumor.
Table 1 Main randomized trials comparing SLNB vs SLNB ? ALND
Trial Year Comparison Population Median FU (months) Recurrence
GIVOM [48] 2008 SLNB ? ALND (if SLNB positive) 352 56 5 years DFS 89.9 %
SLNB ? ALND 345 5 years DFS 87.6 %
NCT00970983 [49] 2010 SLNB ? ALND (if SLNB positive) 257 102 5 years DFS 89.9 %
SLNB ? ALND 476 5 years DFS 89.9 %
NSABP [50] 2010 SLNB alone 2011 95.6 DFS 16.7 %
SLNB ? ALND 1975 DFS 15.9 %
ACOSOG Z0011 [51] 2011 SLNB alone 446 75 5 years DFS 83.9 %
SLNB ? ALND 445 5 years DFS 82.2 %
IBCSG 23-01 [52] 2013 ALND only (after SLNB) 464 60 5 years DFS 84.4 %
No ALND (after SLNB) 467 5 years DFS 87.8 %
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New non-radioactive tracers
SN biopsy and ROLL/SNOLL require radioactive sub-
stances, thus restricting their use to centers with a nuclear
medicine department. This limiting factor probably ex-
plains why, despite the increased incidence of breast can-
cer, the use of SN biopsy has reached a plateau of about
60 % in developed countries that have access to this pro-
cedure [74], decreasing to 5 % in China and the rest of the
world [75]. Recent years have seen the development of
alternative methods that involve the use of non-radioactive
substances. A recent systematic review by Ahmed et al.
[76] analyzed 21 studies on new molecules for SN biopsy,
including fluorescent indocyanine green (ICG), contrast-
enhanced ultrasound (CEUS) using microbubbles, or su-
perparamagnetic iron oxide nanoparticles (SPIO). The au-
thors concluded that the new methods were not superior to
SN biopsy performed with traditional molecules in terms of
the SN detection rate.
Thill et al. [77] recently carried out an international
prospective, multicentre, non-randomized paired
equivalence study on 150 patients with histologically
confirmed breast cancer to evaluate the TSentiMag
technique, a non-radioactive detection system that mag-
netically marks the location of lymph nodes prior to their
surgical removal and subsequent analysis. The authors
detected 291 SNs in 150 patients using both 99mTc and
TsentiMag; the nodal detection rate was 91.8 % for the
radioisotope and 97.3 % for the SPIO tracer, with a nodal
concordance of 98.5 % (263/267; CI 96.5–99.5 %) and a
reverse nodal concordance of 92.9 % (263/283; CI
89.5–95.5 %). It was concluded that magnetic SN biopsy
was comparable with the standard radioactive method in
terms of ease of execution, safety and efficacy. All of the
new technologies require further evaluation in random-
ized controlled trials prior to their introduction into
clinical practice.
Conclusion
SN biopsy has gradually become the standard of care for a
number of solid tumors. In particular, the use of this pro-
cedure in breast cancer has greatly reduced surgical treat-
ment-related morbidity, reducing the number of patients
submitted to unnecessary axillary dissection. It is also easy
to perform and safe for patients and healthcare operators.
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